ArticleExperimental and therapeutic medicine2025
Clinical effectiveness of intraoperative continuous pump infusion of remimazolam on postoperative delirium in elderly patients with hip fractures.
Article in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of Remimazolam on Postoperative Delirium in Elderly Surgical Patients: A Critical Review of Pharmacological Mechanisms and Clinical Evidence.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postoperative delirium (POD) is a prevalent acute central nervous system complication in elderly patients following surgery. The potential of remimazolam, a novel ultrashort-acting benzodiazepine, in mitigating POD after hip fracture surgery remains unclear. The present study aimed to investigate the effects of continuous intraoperative remimazolam infusion on POD in elderly patients with hip fractures undergoing subarachnoid block. A retrospective analysis was conducted on 405 elderly patients who underwent elective hip fracture surgery under subarachnoid block at The 904th Hospital of the Joint Logistics Support Force (Wuxi, China) between January 2019 and December 2023. Patients were divided into two groups based on the intervention received: The remimazolam group (observation group, n=180) and the control group (no remimazolam treatment, n=225). POD was evaluated using the Confusion Assessment Method-Chinese Revision at 1-7 days post-surgery. Anxiety scores were recorded 1 day before and 1 day after surgery. The incidence of intraoperative hypertension, hypotension, bradycardia, hypoxemia, and postoperative nausea and vomiting was also documented. Baseline characteristics were comparable between the two groups, with no significant differences observed in patient demographics. The incidence of POD was significantly lower in the remimazolam group compared with that in the control group (P=0.008). Anxiety scores 1 day post-surgery were also significantly reduced in the remimazolam group (P<0.001). Furthermore, the remimazolam group demonstrated a marked reduction in intraoperative hypertension (P=0.017). No significant differences were observed between the two groups regarding the incidences of intraoperative hypotension, bradycardia, hypoxemia, or postoperative nausea and vomiting. In conclusion, remimazolam appears to reduce the incidence of POD in elderly patients undergoing hip fracture surgery with subarachnoid block, potentially through the alleviation of intraoperative anxiety, without increasing the risk of perioperative complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.